Patent ID: 11970555
Assignee: BICYCLETX LIMITED
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 18:
19. The peptide ligand as defined in claim 1, wherein the molecular scaffold is 1,1′,1″-(1,3,5-triazinane-1,3,5-triyl)tris(2-bromoethanone) (TATB), and said polypeptide comprises an amino acid sequence selected from:
A-(SEQ ID NO: 4)-A (herein referred to as BCY13983);
A-(SEQ ID NO: 4)-A-[Sar6]-[K-Fl] (herein referred to as BCY14474);
A-(SEQ ID NO: 5)-A (herein referred to as BCY13986);
A-(SEQ ID NO: 5)-A-[Sar6]-[K-Fl] (herein referred to as BCY14475);
A-(SEQ ID NO: 6)-A (herein referred to as BCY15466);
Ac-(SEQ ID NO: 6) (herein referred to as BCY15889);
A-(SEQ ID NO: 7)-A (herein referred to as BCY15467);
Ac-(SEQ ID NO: 7) (herein referred to as BCY15890);
A-(SEQ ID NO: 8)-A (herein referred to as BCY13989);
A-(SEQ ID NO: 8)-A-[Sar6]-[K-Fl] (herein referred to as BCY14476);
A-(SEQ ID NO: 9)-A (herein referred to as BCY15468);
A-(SEQ ID NO: 9)-A-[Sar6]-[K-Fl] (herein referred to as BCY15768);
(SEQ ID NO: 9)-[Sar6]-[K-Fl] (herein referred to as BCY15934);
Ac-(SEQ ID NO: 9)-A-[Sar6]-[K-Fl] (herein referred to as BCY15937);
Ac-(SEQ ID NO: 9)-[Sar6]-[K-Fl] (herein referred to as BCY15938);
[Fl]G[Sar5]-A-(SEQ ID NO: 9)-A (herein referred to as BCY15940);
N[1Nal]N-(SEQ ID NO: 9) (herein referred to as BCY18030);
Ac-(SEQ ID NO: 9)-E[Pip]W (herein referred to as BCY18039);
Ac-(SEQ ID NO: 9)-EPW (herein referred to as BCY17994);
NWN-(SEQ ID NO: 9) (herein referred to as BCY18029);
NWN-(SEQ ID NO: 9)-A (herein referred to as BCY17109);
Ac-(SEQ ID NO: 9)-E[Aze]W (herein referred to as BCY18037);
Ac-NWN-(SEQ ID NO: 9) (herein referred to as BCY17992);
Ac-(SEQ ID NO: 9)-E[dP]W (herein referred to as BCY18038);
Ac-N[1Na1]N-(SEQ ID NO: 9) (herein referred to as BCY18034);
N[dW]N-(SEQ ID NO: 9) (herein referred to as BCY18031);
Ac-N[dW]N-(SEQ ID NO: 9) (herein referred to as BCY18035);
HWM-(SEQ ID NO: 9)-A (herein referred to as BCY17110);
A-(SEQ ID NO: 9)-PHP (herein referred to as BCY17115);
A-(SEQ ID NO: 9)-EPW (herein referred to as BCY17114);
NEV-(SEQ ID NO: 9)-A (herein referred to as BCY17112);
A-(SEQ ID NO: 9)-PIVH (herein referred to as BCY17120);
Ac-(SEQ ID NO: 9) (herein referred to as BCY15891);
HTS-(SEQ ID NO: 9)-A (herein referred to as BCY17111);
Ac-N[NMeTrp]N-(SEQ ID NO: 9) (herein referred to as BCY18036);
N[NMeTrp]N-(SEQ ID NO: 9) (herein referred to as BCY18032);
Ac-A-(SEQ ID NO: 9)-A (herein referred to as BCY15939);
A-(SEQ ID NO: 9)-EHQE (herein referred to as BCY17119);
ESF-(SEQ ID NO: 9)-A (herein referred to as BCY17113);
NWN-(SEQ ID NO: 9)-[K(N3)] (herein referred to as BCY17870);
Ac-NWN-(SEQ ID NO: 9)-[K(N3)] (herein referred to as BCY17871);
[AzPro]-NWN-(SEQ ID NO: 9) (herein referred to as BCY17872);
Ac-(SEQ ID NO: 9)-EPW-[K(N3)] (herein referred to as BCY17873);
[AzPro]-(SEQ ID NO: 9)-EPW (herein referred to as BCY17874);
Ac-(SEQ ID NO: 9)-[K(N3)] (herein referred to as BCY17868);
[AzPro]-(SEQ ID NO: 9) (herein referred to as BCY17869);
Ac-N[dY]N-(SEQ ID NO: 9)-[K(N3)] (herein referred to as BCY17882);
Ac-(SEQ ID NO: 9)-E-[dP]-W-[K(N3)] (herein referred to as BCY17890);
Ac-(SEQ ID NO: 9)-E-[Aze]-W-[K(N3)] (herein referred to as BCY17892);
Ac-(SEQ ID NO: 9)-E-[Pip]-W-[K(N3)] (herein referred to as BCY17894);
Ac-(SEQ ID NO: 9)-[K(N3)(PYA-maleimide] (herein referred to as BCY17906);
Ac-(SEQ ID NO: 9)-EPW-[Peg10]-[K(N3)] (herein referred to as BCY19405);
Ac-(SEQ ID NO: 9)-EPW-[Peg24]-[K(N3)] (herein referred to as BCY19406);
Ac-(SEQ ID NO: 9)-EPWGGSGGS-[K(N3)] (herein referred to as BCY19407);
A-(SEQ ID NO: 10)-A (herein referred to as BCY15469);
Ac-(SEQ ID NO: 10) (herein referred to as BCY15892);
A-(SEQ ID NO: 11)-A (herein referred to as BCY15470);
Ac-(SEQ ID NO: 11) (herein referred to as BCY15893);
A-(SEQ ID NO: 12)-A (herein referred to as BCY15471);
Ac-(SEQ ID NO: 12) (herein referred to as BCY15894);
Ac-(SEQ ID NO: 13) (herein referred to as BCY17991);
Ac-(SEQ ID NO: 13)-EPW (herein referred to as BCY17995);
Ac-NWN-(SEQ ID NO: 13) (herein referred to as BCY17993);
NWN-(SEQ ID NO: 13) (herein referred to as BCY18033);
A-(SEQ ID NO: 13)-A (herein referred to as BCY16754);
Ac-(SEQ ID NO: 13)-[K(N3)] (herein referred to as BCY17896);
Ac-NWN-(SEQ ID NO: 13)-[K(N3)] (herein referred to as BCY17899);
Ac-(SEQ ID NO: 13)-EPW-[K(N3)] (herein referred to as BCY17901);
Ac-(SEQ ID NO: 14) (herein referred to as BCY17990);
Ac-(SEQ ID NO: 14)-[K(N3)] (herein referred to as BCY17875);
[AzPro]-(SEQ ID NO: 14) (herein referred to as BCY17876);
Ac-(SEQ ID NO: 15) (herein referred to as BCY17989);
A-(SEQ ID NO: 15)-A (herein referred to as BCY16047);
Ac-(SEQ ID NO: 15)-[K(N3)] (herein referred to as BCY17877);
[AzPro]-(SEQ ID NO: 15) (herein referred to as BCY17878);
A-(SEQ ID NO: 16)-A (herein referred to as BCY16962);
TYMN-(SEQ ID NO: 17)-A (herein referred to as BCY17117);
A-(SEQ ID NO: 17)-A (herein referred to as BCY16048);
A-(SEQ ID NO: 18)-A (herein referred to as BCY16963);
Ac-(SEQ ID NO: 19) (herein referred to as BCY17987);
A-(SEQ ID NO: 20)-A (herein referred to as BCY16753);
A-(SEQ ID NO: 21)-A (herein referred to as BCY16046);
A-(SEQ ID NO: 22)-A (herein referred to as BCY16964);
A-(SEQ ID NO: 23)-A (herein referred to as BCY16965);
Ac-(SEQ ID NO: 24) (herein referred to as BCY17986);
A-(SEQ ID NO: 25)-A (herein referred to as BCY16550);
A-(SEQ ID NO: 26)-A (herein referred to as BCY16966);
A-(SEQ ID NO: 27)-A (herein referred to as BCY16051);
IDSN-(SEQ ID NO: 28)-A (herein referred to as BCY17118);
WGKS-(SEQ ID NO: 29)-A (herein referred to as BCY17116);
A-(SEQ ID NO: 30)-A (herein referred to as BCY16053);
A-(SEQ ID NO: 31)-A (herein referred to as BCY16557);
A-(SEQ ID NO: 32)-A (herein referred to as BCY16035);
A-(SEQ ID NO: 33)-A (herein referred to as BCY16043);
A-(SEQ ID NO: 34)-A-[Sar6]-[K-Fl] (herein referred to as BCY15769);
A-(SEQ ID NO: 35)-A (herein referred to as BCY15648);
A-(SEQ ID NO: 36)-A (herein referred to as BCY16031);
A-(SEQ ID NO: 37)-A (herein referred to as BCY16079);
A-(SEQ ID NO: 38)-A (herein referred to as BCY16036);
A-(SEQ ID NO: 39)-A (herein referred to as BCY16029);
A-(SEQ ID NO: 40)-A (herein referred to as BCY16089);
A-(SEQ ID NO: 41)-A (herein referred to as BCY16088);
A-(SEQ ID NO: 42)-A (herein referred to as BCY16052);
A-(SEQ ID NO: 43)-A (herein referred to as BCY16033);
A-(SEQ ID NO: 44)-A (herein referred to as BCY16039);
Ac-(SEQ ID NO: 44) (herein referred to as BCY17988);
Ac-(SEQ ID NO: 44)-[K(N3)] (herein referred to as BCY17879);
[AzPro]-(SEQ ID NO: 44) (herein referred to as BCY17880);
A-(SEQ ID NO: 45)-A (herein referred to as BCY16038);
A-(SEQ ID NO: 46)-A (herein referred to as BCY16050);
A-(SEQ ID NO: 47)-A (herein referred to as BCY16034);
A-(SEQ ID NO: 48)-A (herein referred to as BCY16032);
A-(SEQ ID NO: 49)-A (herein referred to as BCY16049);
A-(SEQ ID NO: 50)-A (herein referred to as BCY16558);
A-(SEQ ID NO: 51)-A (herein referred to as BCY16041);
A-(SEQ ID NO: 52)-A (herein referred to as BCY16042);
A-(SEQ ID NO: 53)-A (herein referred to as BCY16045);
A-(SEQ ID NO: 54)-A (herein referred to as BCY16037);
A-(SEQ ID NO: 55)-A (herein referred to as BCY16044);
A-(SEQ ID NO: 56)-A (herein referred to as BCY16040);
A-(SEQ ID NO: 57)-A-[Sar6]-[K-Fl] (herein referred to as BCY15771);
A-(SEQ ID NO: 58)-A-[Sar6]-[K-Fl] (herein referred to as BCY15772);
A-(SEQ ID NO: 59)-A-[Sar6]-[K-Fl] (herein referred to as BCY15773);
A-(SEQ ID NO: 60)-A-[Sar6]-[K-Fl] (herein referred to as BCY15774);
A-(SEQ ID NO: 61)-A-[Sar6]-[K-Fl] (herein referred to as BCY15775);
A-(SEQ ID NO: 62)-A-[Sar6]-[K-Fl] (herein referred to as BCY15776);
A-(SEQ ID NO: 63)-A-[Sar6]-[K-Fl] (herein referred to as BCY15777);
A-(SEQ ID NO: 64)-A-[Sar6]-[K-Fl] (herein referred to as BCY15770);
Ac-(SEQ ID NO: 65) (herein referred to as BCY17903);
Ac-(SEQ ID NO: 66) (herein referred to as BCY17904); and
Ac-(SEQ ID NO: 67) (herein referred to as BCY17905);, wherein AzPro represents azidopropyl, Aze represents azetidine, 1Nal represents 1-naphthylalanine, NMeTrp represents N-methyl-tryptophan, [K(N3)] represents 6-azido lysine, Peg represents polyethylene glycol, Pip represents pipecolic acid, Sar represents sarcosine, Fl represents fluorescein and [K(N3)(PYA-Maleimide)] represents a modified lysine having a structure:,